Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis.
OBJECTIVE
To determine whether systemic antifungal prophylaxis decreases infectious morbidity and mortality in nonneutropenic, critically ill, trauma and surgical intensive care unit (ICU) adult patients.


METHODS
Systematic review and meta-analysis of randomized clinical trials. We used a fixed effect model, with risk ratio (RR) and 95% confidence intervals (CI).


METHODS
Patients admitted to ICU after surgery or trauma, with multiple risk factors for fungal infections.


METHODS
Nine studies (seven double blind) with a total of 1,226 patients compared ketoconazole (three) or fluconazole (six) to placebo (eight) or no treatment (one).


RESULTS
Prophylaxis with azole was associated with reduced rates of candidemia (RR 0.30, 95% CI 0.10-0.82), mortality attributable to Candida infection (RR 0.25, 95% CI 0.08-0.80), and overall mortality (RR 0.60, 95% CI 0.45-0.81). Time to event analysis showed a significantly lower probability of fungal infections in treated patients. There was no evidence of statistical heterogeneity between studies, and publication bias assessment gave a negative results. There was, however, wide variability in the definition and reporting of some relevant clinical outcomes (e.g., confirmed or suspected infections, colonization) and pooling of these outcome measures was not feasible.


CONCLUSIONS
Prophylaxis of candidal infection among critically ill ICU patients has beneficial effect on certain outcome measures, but additional data from well designed clinical trials and long-term epidemiological observations are needed to provide firm recommendations for the selection of subgroups of patients who would most benefit from prophylaxis and to determine the effect of prophylaxis on fungal resistance patterns.
Cruciani
Mario
M
HIV Outpatient Clinic, Centre of Preventive Medicine, Via Germania 20, 37135, Verona, Italy. crucianimario@virgilio.it
de Lalla
Fausto
F
Mengoli
Carlo
C
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D007362:Intensive Care Units; D016032:Randomized Controlled Trials as Topic; D012306:Risk
D000935:Antifungal Agents